Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Next Previous
Trial Profile

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonapegsomatropin (Primary) ; Navepegritide (Primary)
  • Indications Achondroplasia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms COACH
  • Sponsors Ascendis Pharma

Most Recent Events

  • 12 Nov 2025 According to an Ascendis Pharma media release, company anticipate presenting 52-week data from this study in early 2026.
  • 02 Sep 2025 According to an Ascendis Pharma media release, the company announced that 26 week results from the study will be presented at ASBMR 2025, the annual meeting of the American Society for Bone & Mineral Research being held in Seattle from September 5-8, 2025.
  • 09 Jun 2025 According to an Ascendis Pharma media release, Ascendis Pharma will host a conference call and webcast today at 8:00 am Eastern Time (ET) to discuss these results. This interim analysis (week 26) will be followed by Week 52 data, expected in Q4 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top